November 17, 2006 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise on the use of carvedilol tablets in diabetic patients; the risk for potentially fatal ...

The U.S. Food and Drug Administration today approved the first generic versions of Coreg (carvedilol). Coreg is a widely used medication that is FDA-approved to treat high blood pressure, mild to ...

The Supreme Court declined to hear Teva's challenge to a $235 million award to GlaxoSmithKline in a patent dispute over generic drugs involving heart medication Coreg, according to a Reuters report.

Prove it, GlaxoSmithKline. So says a judge in the Coreg patent case that last year ended in a $235 million judgment against generics maker Teva. In the patent "carve-out" case, GSK didn't bring enough ...

Carvedilol could be the poster child for how to lower drug prices. Since 2007, over 20 million patients with cardiovascular conditions have enjoyed generic versions of the popular beta-blocker, which ...

This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. July 22, ...

A low-dose regimen of the blood pressure medication carvedilol demonstrated safety and efficacy in improving heart health of childhood cancer survivors, according to results of a multicenter phase 2b ...

NEW YORK Teva has settled a case against Dr. Reddy’s concerning its patent on carvedilol, the active ingredient in GlaxoSmithKline’s heart drug Coreg. Teva started filing suits last June to protect ...

(Reuters) - A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million (£185 million) for infringing a patent covering its blood pressure drug Coreg, ...

GlaxoSmithKline’s heart drug Coreg has been around a good long while, but it still pumps out more revenue for the U.K. drug company to keep fighting patent battles for the drug. Teva now finds itself ...